Discovery of Root Cause of Triple-Negative Breast Cancer May Lead to New Therapies
March 5, 2014
TNBC comprises about 15-20 percent of all breast cancer diagnoses; disproportionately affects women of African and Hispanic descent.
Dual Therapeutics, a New Oncology Start-up, Is Launched by BioMotiv and the Icahn School of Medicine at Mount Sinai
October 9, 2013
Dual Therapeutics is based on intellectual property exclusively licensed from the Icahn School of Medicine at Mount Sinai.
Chemical Compound Shows Promise as Alternative to Opioid Pain Relievers
July 1, 2013
Drug targeting a protein complex containing two different types of opioid receptors may be an effective alternative to morphine and other opioid pain medications.
Researchers Discover Clues to Developing More Effective Antipsychotic Drugs
November 23, 2011
Mount Sinai has identified the pattern of cell signaling induced by antipsychotic drugs in a complex composed of two brain receptors linked to schizophrenia.
Mount Sinai School of Medicine Researchers Discover Mechanism by Which Diseases Develop
July 8, 2010
Researchers have identified a previously unknown mechanism by which information from a gene is used to direct the physical and behavioral development of individuals.
Mount Sinai Researchers Find Structural Basis for Incidence of Skin Cancers in a Genetic Disorder
June 23, 2010
Researchers from Mount Sinai School of Medicine have found why patients with an inherited genetic disorder are more susceptible to skin cancers than the general population.
Mount Sinai School of Medicine Significantly Improves Its U.S. News & World Report Best Graduate Schools Rankings
April 24, 2009
Over the past four years, Mount Sinai has improved in the U.S. News & World Report "America's Best Graduate Schools" rankings more than any other school in the United States, jumping from 32nd to 22nd.
Fax: 212-849 -2456
Fax: 212-849 -2456
Icahn School of Medicine at Mount
Sinai, Department of Structural &
One Gustave L. Levy Place, Box 1677
New York, NY 10029